Company
Abbott
Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
282
510(k), De Novo and PMA
Device trials
550
As lead sponsor, any status
Adverse event reports
524,059
Received Nov 1, 2025 to Nov 19, 2026
Recall records
1,086
One per recalled product
Abbott is on our public-company list (ticker ABT). Names searched as well: Abbott Vascular, Abbott Medical, Abbott Diabetes Care, St. Jude Medical. Naming a company here is not a recommendation of it or of any security.
Financing
Public company. Figures from its SEC financial statements, plus private placements it reported on Form D.
Listed
ABT
NYSE · ABBOTT LABORATORIES
Public float
$232.2B
Value of shares held by non-insiders on Jun 30, 2025
Revenue
$44.3B
Fiscal year ending Dec 31, 2025
Net income
$6.52B
Fiscal year ending Dec 31, 2025
R&D spending
$2.94B
Fiscal year ending Dec 31, 2025
Cash
$4.05B
As of Sep 30, 2026
Long-term debt
$29.5B
As of Sep 30, 2026
Shares outstanding
1731.9M
As of Sep 30, 2026
Capital raised as a public company
Cash received from selling stock and borrowing, from each year's cash-flow statement in the annual report. Fiscal years, by the year each one ended.
| Year | IPO | Stock sold | Long-term debt | Convertible debt |
|---|---|---|---|---|
| 2021 | – | – | $4.0M | – |
Private placements (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
| First sale | Type | Raised | Round size | Investors | Exemption and agent | Filing |
|---|---|---|---|---|---|---|
| Mar 1, 2011 | Debt | $100K | $100K | 1 | Rule 506Agent: Goldman Sachs & Co.Commissions $200 | Form D ↗Mar 15, 2011 |
| Mar 1, 2010 | Debt | $70K | $70K | 1 | Rule 506Agent: Goldman, Sachs & Co.Commissions $140 | Form D/A ↗Mar 12, 20101 amendment |
Company details
From the company's latest Form D.
- Legal name
- ABBOTT LABORATORIES
- Headquarters
- Abbott Park, Illinois
- Incorporated
- Illinois over five years before filing
- Entity type
- Corporation
- Revenue range
- Over $100,000,000
- Industry filed under
- Pharmaceuticals
- SEC filer
- CIK 1800 ↗
Executives, directors and promoters
As listed on the latest Form D.
- Carlos AlbanExecutive Officer
- William SmithburgDirector
- Glenn TiltonDirector
- Edward MichaelExecutive Officer
- Roxanne AustinDirector
- Greg LinderExecutive Officer
- Edward LiddyDirector
- James MazzoExecutive Officer
- John CapekExecutive Officer
- John LandgrafExecutive Officer
- Mary SzelaExecutive Officer
- Miles WhiteExecutive Officer, Director
- Heather MasonExecutive Officer
- William OsbornDirector
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
The investor database is part of the paid tier
It is included for signed-in readers who have credit, along with the daily news digest. Credit is also what pays for AI device summaries.
Latest FDA decisions
The 8 newest of 282 since 2015.
P260019 · Decided Oct 27, 2026 · 180 days after receipt
Device type: Para-device leak occluder (SJT) · Cardiology
- Anti-HCV Next510(k)
K262156 · Decided Sep 23, 2026 · 89 days after receipt
Device type: Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus (MZO) · Laboratory Medicine & Pathology
- EnSite X EP System510(k)
K261729 · Decided Sep 17, 2026 · 114 days after receipt
Device type: Computer, Diagnostic, Programmable (DQK) · Cardiology
- TactiFlex Duo Ablation Catheter, Sensor Enabled (A-TFDM-D, A-TFDM-F, A-TFDM-J, A-TFDM-DD, A-TFDM-DF, A-TFDM-FF, A-TFDMPMA supplement
P220013-S028 · Decided Sep 4, 2026 · 186 days after receipt · Panel Track
Device type: Catheter, percutaneous, cardiac ablation, for treatment of atrial fibrillation (OAE) · Cardiology
K262747 · Decided Aug 31, 2026 · 28 days after receipt
Device type: Respiratory Virus Panel Nucleic Acid Assay System (OCC) · Laboratory Medicine & Pathology
- Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring SystemNew device typeDe Novo
DEN250049 · Decided Aug 25, 2026 · 330 days after receipt
Device type: Integrated Continuous Glucose Ketone Monitoring System (SJD) · Laboratory Medicine & Pathology
- EnSite X EP System510(k)
K262006 · Decided Jul 15, 2026 · 30 days after receipt
Device type: Computer, Diagnostic, Programmable (DQK) · Cardiology
K261825 · Decided Jul 2, 2026 · 30 days after receipt
Device type: Catheter, Percutaneous (DQY) · Cardiology
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- Portico Next Generation Approval StudyActive, not recruiting
NCT04011722 · 333 participants · Start Sep 17, 2019 · Primary completion Jan 12, 2023
Device: Portico™ NG (Navitor) Valve and FlexNav™ Delivery System; Navitor Titan Valve (35mm) Valve and Large FlexNav™ Delivery System · For: Symptomatic Severe Aortic Stenosis
Sites: Los Angeles, California; Thousand Oaks, California; Washington D.C., District of Columbia · 28 sites in all
- Abbott Structural Heart Device RegistryRecruiting
NCT06590467 · 2,500 participants (planned) · Start Aug 21, 2024 · Primary completion Dec 2029
Device: Amplatzer™ Occlusion Devices; Epic™ Surgical Tissue Heart Valve devices · For: Heart Diseases; ASD - Atrial Septal Defect; VSD - Muscular Ventricular Septal Defect and 3 more
Sites: Los Angeles, California; Washington D.C., District of Columbia; Miami, Florida · 36 sites in all
NCT07798726 · 565 participants (planned) · Start Oct 21, 2026 · Primary completion Dec 31, 2031
Device: Cephea Mitral Valve System · For: Mitral Valve Disease; Mitral Annulus Calcification; Mitral Regurgitation and 6 more
Sites: Wichita, Kansas
- Validation Of anatomY-specific Aortic Valve Implantation Guided by Software Using EncantoRNot yet recruiting
NCT07696182 · 300 participants (planned) · Start Nov 30, 2026 · Primary completion Sep 30, 2028
Device: Transcatheter valve replacement therapy · For: Severe Native Calcific Aortic Stenosis; Symptomatic Heart Disease Due to Severe Native Calcific Aortic Stenosis
Sites: Chermside, Australia; Clayton, Australia; Melbourne, Australia · 36 sites in all
NCT07586995 · 1,000 participants (planned) · Start Jul 2, 2026 · Primary completion Sep 2028
Device: Tricuspid Transcatheter Edge-to-Edge Repair (TEER) · For: Tricuspid Regurgitation (TR)
Sites: Phoenix, Arizona; La Jolla, California; Chicago, Illinois · 14 sites in all
- Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart FailurePivotal-lookingRecruiting
NCT06526195 · 850 participants (planned) · Start Dec 13, 2024 · Primary completion Sep 2029
Device: CardioMEMS HF System; HeartMate 3 Left Ventricular Assist System · For: Heart Failure; Heart Diseases; Cardiovascular Diseases and 1 more
Sites: Phoenix, Arizona; Little Rock, Arkansas; Sacramento, California · 70 sites in all
Reports received
524,059
Received Nov 1, 2025 to Nov 19, 2026. Includes 155 of another or unstated type.
Malfunction reports
474,836
91% of reports
Injury reports
47,775
9.1% of reports
Death reports
1,293
0.2% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 4,584 | 4,630 | 61 | 0 |
| Jan 24 | 5,202 | 5,040 | 67 | 4 |
| Feb 24 | 4,606 | 4,870 | 106 | 0 |
| Mar 24 | 4,456 | 4,917 | 67 | 2 |
| Apr 24 | 5,601 | 5,140 | 64 | 0 |
| May 24 | 5,396 | 5,215 | 108 | 3 |
| Jun 24 | 4,797 | 5,134 | 62 | 0 |
| Jul 24 | 5,944 | 5,143 | 60 | 1 |
| Aug 24 | 6,572 | 5,465 | 80 | 1 |
| Sep 24 | 5,422 | 5,042 | 66 | 1 |
| Oct 24 | 5,632 | 5,461 | 100 | 1 |
| Nov 24 | 5,075 | 4,813 | 88 | 2 |
| Dec 24 | 4,820 | 5,169 | 68 | 1 |
| Jan 25 | 5,087 | 4,321 | 80 | 0 |
| Feb 25 | 5,116 | 4,258 | 85 | 3 |
| Mar 25 | 5,561 | 4,506 | 90 | 0 |
| Apr 25 | 6,165 | 4,601 | 111 | 1 |
| May 25 | 5,916 | 4,391 | 87 | 1 |
| Jun 25 | 6,143 | 4,630 | 135 | 1 |
| Jul 25 | 7,197 | 4,608 | 105 | 2 |
| Aug 25 | 6,259 | 4,552 | 150 | 0 |
| Sep 25 | 6,055 | 4,081 | 74 | 0 |
| Oct 25 | 5,885 | 4,118 | 121 | 2 |
| Nov 25 | 5,664 | 3,302 | 118 | 1 |
| Dec 25 | 7,921 | 4,112 | 125 | 0 |
| Jan 26 | 8,365 | 3,448 | 127 | 5 |
| Feb 26 | 5,737 | 3,581 | 114 | 1 |
| Mar 26 | 10,495 | 3,984 | 106 | 2 |
| Apr 26 | 39,946 | 4,393 | 112 | 2 |
| May 26 | 44,472 | 4,406 | 120 | 0 |
| Jun 26 | 48,027 | 4,437 | 123 | 0 |
| Jul 26 | 35,005 | 4,292 | 89 | 34 |
| Aug 26 | 132,594 | 3,976 | 98 | 85 |
| Sep 26 | 117,577 | 4,116 | 80 | 13 |
| Oct 26 | 19,033 | 3,728 | 81 | 12 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
- FREESTYLE LIBRE 3127,752
- FreeStyle Libre 2113,754
- FreeStyle Libre 3 Plus112,598
- FreeStyle Libre 2 Plus65,466
- FreeStyle Libre 14 Day19,028
- FreeStyle LibreLink6,932
- TENDRIL STS4,261
- FREESTYLE NEO2,165
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0191-2027 · Started Sep 10, 2026 · Posted by FDA Oct 16, 2026
Reason given: Changes to Instructions for Use (IFU) for the device regarding risk of Pulmonary Artery Injury (PAI).
Cause as FDA categorized it: Labeling design · Device type: System, Appendage Closure, Left Atrial (NGV)
- Merlin" Patient Care System (PCS) software Merlin" PCS 3650 programmer Model 3330 softwareOpen, Classified
Z-2405-2026 · Started May 12, 2026 · Posted by FDA Jun 11, 2026
Reason given: Software malfunction may occur during pacing capture threshold test of pacemaker resulting in programmer not successfully communicating the command to terminate the test.
Cause as FDA categorized it: Software Design Change · Device type: Leadless Pacemaker (PNJ)
- i-STAT EG7+ cartridge; List Number: 03P76-25;Open, Classified
Z-1999-2026 · Started Apr 1, 2026 · Posted by FDA Apr 29, 2026
Reason given: Approximately 7.6% of cartridges from specific i-STAT EG7+ (list number 03P76-25), i-STAT EG6+ (list number 03P77-25) and i-STAT G3+ (list number 03P78-26) cartridge lots in the U.S. marketplace may report higher than expected PCO2 and lower than expected pH results due to a manufacturing issue. A falsely high pCO2...
Cause as FDA categorized it: Process change control · Device type: Electrode Measurement, Blood-Gases (Pco2, Po2) And Blood Ph (CHL)
- i-STAT EG6+ cartridge; List Number: 03P77-25;Open, Classified
Z-2000-2026 · Started Apr 1, 2026 · Posted by FDA Apr 29, 2026
Reason given: Approximately 7.6% of cartridges from specific i-STAT EG7+ (list number 03P76-25), i-STAT EG6+ (list number 03P77-25) and i-STAT G3+ (list number 03P78-26) cartridge lots in the U.S. marketplace may report higher than expected PCO2 and lower than expected pH results due to a manufacturing issue. A falsely high pCO2...
Cause as FDA categorized it: Process change control · Device type: Electrode Measurement, Blood-Gases (Pco2, Po2) And Blood Ph (CHL)
- i-STAT G3+ cartridge; List Number: 03P78-26;Open, Classified
Z-2001-2026 · Started Apr 1, 2026 · Posted by FDA Apr 29, 2026
Reason given: Approximately 7.6% of cartridges from specific i-STAT EG7+ (list number 03P76-25), i-STAT EG6+ (list number 03P77-25) and i-STAT G3+ (list number 03P78-26) cartridge lots in the U.S. marketplace may report higher than expected PCO2 and lower than expected pH results due to a manufacturing issue. A falsely high pCO2...
Cause as FDA categorized it: Process change control · Device type: Electrode Measurement, Blood-Gases (Pco2, Po2) And Blood Ph (CHL)
Z-1565-2026 · Started Feb 9, 2026 · Posted by FDA Mar 13, 2026
Reason given: It was confirmed that the impacted lot has a higher occurrence of invalid rates when compared to the product Instructions for Use.
Cause as FDA categorized it: Under Investigation by firm · Device type: Influenza A And Influenza B Multiplex Nucleic Acid Assay (OZE)
Z-1020-2026 · Started Nov 24, 2025 · Posted by FDA Jan 14, 2026
Reason given: Due to a manufacturing process issue that may cause carbon build up in the sensor that may result in incorrect low glucose results
Cause as FDA categorized it: Process control · Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated, Not For Use With Automated Insulin Delivery Systems (QLG)
Z-1021-2026 · Started Nov 24, 2025 · Posted by FDA Jan 14, 2026
Reason given: Due to a manufacturing process issue that may cause carbon build up in the sensor that may result in incorrect low glucose results
Cause as FDA categorized it: Process control · Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated, Not For Use With Automated Insulin Delivery Systems (QLG)
Showing the 8 newest of 1,086 recall records in FDA's data.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.